NOvAN

Novan, Inc. was a clinical-stage biotechnology company that aimed to leverage its proprietary nitric oxide-releasing platform, NITRICIL™, to create novel, first-in-class therapies for a variety of skin diseases. The company's primary focus was on developing treatments for conditions like molluscum contagiosum, acne vulgaris, and other dermatological ailments. Founded in 2008, Novan was a publicly-traded company that advanced several product candidates through clinical trials. In July 2023, the company filed for Chapter 11 bankruptcy protection and its assets, including its lead product candidate berdazimer gel, were subsequently acquired by Ligand Pharmaceuticals.